Physician profile
Christopher Rowan
NPI 1477783264
$48,324.63
in general payments reported to CMS, 2019-2025
36 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $9,659 · 2021: $15K · 2022: $12K · 2023: $8,087 · 2024: $908 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $4,334 · Travel and Lodging: $1,004 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $4,334.33 |
| Travel and Lodging | $1,003.62 |
| Education | $131.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30,694.72 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $11,610.05 | 2020-2024 | Farxiga, Wainua |
| Abbott Laboratories | $1,644.83 | 2019-2023 | Accent, Jot Dx, Amplatzer Talisman |
| Novartis Pharmaceuticals Corporation | $620.07 | 2021-2025 | |
| United Therapeutics Corporation | $507.64 | 2023-2025 | Tyvaso, Orenitram, Orenitram |
| Actelion Pharmaceuticals US, INC. | $446.11 | 2023-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $224.41 | 2021-2025 | |
| Medtronic, INC. | $208.77 | 2023-2024 | Abre, Reveal Linq, Mycarelink |
| Scpharmaceuticals INC. | $206.54 | 2023-2025 | |
| Philips North America LLC | $197.09 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Merck Sharp & Dohme LLC | $188.31 | 2023-2025 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $186.25 | 2019 | |
| Amgen INC. | $168.17 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $153.17 | 2021-2025 | |
| Abiomed | $146.59 | 2020-2023 | Impella |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $133.68 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $119.09 | 2023 | Sapien 3 Ultra Resilia |
| Lexicon Pharmaceuticals, INC. | $114.96 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $102.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.56 | 2023 | Jardiance |
| Boston Scientific Corporation | $89.99 | 2022-2023 | Latitude Communicator Power Supply, S-Icd System Magnet |
| Novo Nordisk INC | $85.00 | 2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $53.48 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $49.58 | 2023-2024 | Onpattro |
| Shockwave Medical, INC | $45.78 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $41.14 | 2023 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $31.84 | 2024 | Arcalyst |
| Biotronik INC. | $26.85 | 2022 | |
| Tactile Systems Technology INC | $24.91 | 2025 | Nimbl, Flexitouch Plus |
| Atricure, INC. | $22.67 | 2024 | |
| Irhythm Technologies, INC. | $20.25 | 2023 | Zio Xt Patch |
| Johnson & Johnson Health Care Systems INC. | $19.71 | 2023 | Opsumit |
| Chiesi USA, INC. | $17.21 | 2024 | Kengreal, Cleviprex |
| Esperion Therapeutics, INC. | $16.78 | 2023 | Nexletol |
| Cardiva Medical, INC. | $16.42 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.